Cytokine Storms and Silent Killers: Immune Dysregulation in Cancer Progression

Cytokines are central mediators of immune communication, orchestrating interactions between innate and adaptive immune cells. In cancer, dysregulated cytokine signaling drives chronic inflammation, immune suppression, and tumor progression. This narrative review synthesizes current mechanistic and clinical insights into cytokine dysregulation, explicitly distinguishing acute systemic cytokine release syndrome (CRS), often observed during CAR-T cell therapy, from chronic, tumor-localized cytokine amplification within the tumor microenvironment (TME). We discuss key signaling pathways including IL-6/STAT3, TNF-α/NF-κB, and TGF-β/SMAD highlighting context-, tumor-, and dose-dependent effects on epithelial-to-mesenchymal transition (EMT), therapy resistance, immune exhaustion, and angiogenesis. The review integrates translational evidence linking cytokine activity to tumor type, biomarkers, patient stratification, and outcomes from both successful and failed clinical trials. Conceptual schematics and tables provide visual summaries of cytokine interactions, immunosuppressive networks, and therapeutic targets. Limitations, including the non-novel nature of the mechanisms discussed, selective clinical coverage, and context-specific variability, are explicitly addressed. By consolidating mechanistic and clinical knowledge, this review offers a focused perspective on cytokine dysregulation, informing translational strategies to modulate the tumor immune landscape.